| 1 |
Core outcome measures for chronic pain clinical trials: IMMPACT recommendations
Robert H. Dworkin et al. · Pain
|
6 Nov 2004 |
3,789 |
| 2 |
Core outcome domains for chronic pain clinical trials: IMMPACT recommendations
Dennis C. Turk et al. · Pain
|
22 Sep 2003 |
3,518 |
| 3 |
Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations
Robert H. Dworkin et al. · Journal of Pain
Open access |
13 Dec 2007 |
3,496 |
| 4 |
Perspectives on cancer therapy-induced mucosal injury
Stephen T. Sonis, Linda S. Elting, Dorothy M. K. Keefe et al. · Cancer
Open access |
2004 |
1,420 |
| 5 |
Core Outcome Domains and Measures for Pediatric Acute and Chronic/Recurrent Pain Clinical Trials: PedIMMPACT Recommendations
Patrick J. McGrath et al. · Journal of Pain
Open access |
18 Jun 2008 |
862 |
| 6 |
Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis
Edward B. Rubenstein, Douglas E. Peterson, Mark Schubert et al. · Cancer
|
2004 |
828 |
| 7 |
The burdens of cancer therapy
Linda S. Elting, Catherine D. Cooksley, Mark Steven Chambers et al. · Cancer
Open access |
14 Aug 2003 |
621 |
| 8 |
Double‐blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy
Yadollah Harati, Clifton L. Gooch, Michael Swenson et al. · Neurology
|
Jun 1998 |
544 |
| 9 |
Migraine prevalence by age and sex in the United States: A life-span study
TW Victor, Xiaojun Hu, JC Campbell et al. · Cephalalgia
Open access |
12 Mar 2010 |
517 |
| 10 |
SPSS-X Advanced Statistics Guide
Mark Von Tress · Technometrics
|
May 1988 |
496 |
| 11 |
Patient-Controlled Analgesia
Jeffrey A. Grass · Anesthesia & Analgesia
|
12 Oct 2005 |
451 |
| 12 |
Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations
Robert H. Dworkin et al. · Pain
|
9 Mar 2010 |
386 |
| 13 |
Increased Prevalence of Metabolic Syndrome in Individuals with Osteoarthritis: An Analysis of NHANES III Data
R. Puenpatom, Timothy W. Victor · Postgraduate Medicine
|
Nov 2009 |
358 |
| 14 |
PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial
Sheena McCormack et al. · The Lancet
Open access |
21 Sep 2010 |
336 |
| 15 |
Complex regional pain syndrome: are there distinct subtypes and sequential stages of the syndrome?
Stephen P. Bruehl, Norman R. Harden, Bradley S. Galer et al. · Pain
|
2002 |
309 |
| 16 |
Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations
Dennis C. Turk et al. · Pain
|
26 Oct 2006 |
305 |
| 17 |
Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations
Robert H. Dworkin et al. · Pain
|
9 Apr 2012 |
293 |
| 18 |
Case fatality and population mortality associated with anaphylaxis in the United States
Larry Ma, Theodore M. Danoff, Larry Borish · Journal of Allergy and Clinical Immunology
Open access |
14 Dec 2013 |
246 |
| 19 |
The Role of Intrathecal Drugs in the Treatment of Acute Pain
James P. Rathmell, Timothy R. Lair, Bushra Nauman · Anesthesia & Analgesia
|
12 Oct 2005 |
245 |
| 20 |
Clinical Application of Opioid Equianalgesic Data
Arnold R. Gammaitoni, Perry G. Fine, Nancy A. Álvarez et al. · Clinical Journal of Pain
|
27 Aug 2003 |
244 |
| 21 |
The Lidocaine Patch 5% Effectively Treats All Neuropathic Pain Qualities: Results of a Randomized, Double-Blind, Vehicle-Controlled, 3-Week Efficacy Study With Use of the Neuropathic Pain Scale
Bradley S. Galer, Mark P. Jensen, Tina Ma et al. · Clinical Journal of Pain
|
Sep 2002 |
243 |
| 22 |
Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women
Salim S. Abdool Karim, Barbra A. Richardson, Gita Ramjee et al. · AIDS
Open access |
16 Feb 2011 |
234 |
| 23 |
Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations
Dennis C. Turk et al. · Pain
|
16 Aug 2008 |
219 |
| 24 |
Safety and Tolerability of the Lidocaine Patch 5%, a Targeted Peripheral Analgesic: A Review of the Literature
Arnold R. Gammaitoni, Nancy A. Álvarez, Bradley S. Galer · The Journal of Clinical Pharmacology
|
Feb 2003 |
203 |
| 25 |
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
Karim S. Fizazi, Christophe Massard, Petri Bono et al. · The Lancet Oncology
Open access |
25 Jun 2014 |
196 |
| 26 |
Prinzmetal's variant form of angina pectoris. Re-evaluation of mechanisms.
Masahiro Endo, I Kanda, S Hosoda et al. · Circulation
Open access |
Jul 1975 |
189 |
| 27 |
Review of Lidocaine Patch 5% Studies in the Treatment of Postherpetic Neuralgia
Pamela Stitzlein Davies, Bradley S. Galer · Drugs
|
2004 |
181 |
| 28 |
Efficacy and Safety of OPANA ER (Oxymorphone Extended Release) for Relief of Moderate to Severe Chronic Low Back Pain in Opioid-Experienced Patients: A 12-Week, Randomized, Double-blind, Placebo-controlled Study
Martin E Hale, Harry B Ahdieh, Tina Ma et al. · Journal of Pain
Open access |
5 Dec 2006 |
170 |
| 29 |
The Pain Quality Assessment Scale: Assessment of Pain Quality in Carpal Tunnel Syndrome
Mark P. Jensen, Arnold R. Gammaitoni, David Olufemi Olaleye et al. · Journal of Pain
Open access |
Nov 2006 |
162 |
| 30 |
Melanoma, Version 2.2013
Daniel G. Coit et al. · Journal of the National Comprehensive Cancer Network
|
Apr 2013 |
155 |
| 31 |
Fatigue properties of AlSi10Mg produced by Additive Layer Manufacturing
Julius N. Domfang Ngnekou, Yves Nadot, Gilbert Hénaff et al. · International Journal of Fatigue
Open access |
4 Oct 2018 |
147 |
| 32 |
Challenges in the Development of Prescription Opioid Abuse-deterrent Formulations
Nathaniel P. Katz, Edgar H. Adams, Howard D. Chilcoat et al. · Clinical Journal of Pain
|
Oct 2007 |
146 |
| 33 |
Research design considerations for chronic pain prevention clinical trials
Jennifer S. Gewandter et al. · Pain
Open access |
16 Apr 2015 |
145 |
| 34 |
Symptom Profiles Differ in Patients With Neuropathic Versus Non-neuropathic Pain
Robert H. Dworkin, Mark P. Jensen, Arnold R. Gammaitoni et al. · Journal of Pain
Open access |
2 Sep 2006 |
139 |
| 35 |
A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain
Nathaniel P. Katz, Richard L Rauck, Harry B Ahdieh et al. · Current Medical Research and Opinion
|
11 Dec 2006 |
136 |
| 36 |
Respiratory Depression After Neuraxial Opioids in the Obstetric Setting
Brendan Carvalho · Anesthesia & Analgesia
|
13 Aug 2008 |
135 |
| 37 |
OKT3 MONOCLONAL ANTIBODY PLASMA LEVELS DURING THERAPY AND THE SUBSEQUENT DEVELOPMENT OF HOST ANTIBODIES TO OKT3
Gideon Goldstein, Anthony J. Fuccello, Douglas J. Norman et al. · Transplantation
|
Nov 1986 |
123 |
| 38 |
Oxymorphone Extended-Release Tablets Relieve Moderate to Severe Pain and Improve Physical Function in Osteoarthritis: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase III Trial
Alan K. Matsumoto, Najib Babul, Harry B Ahdieh · Pain Medicine
|
Sep 2005 |
118 |
| 39 |
Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale
Charles E. Argoff, Bradley S. Galer, Mark P. Jensen et al. · Current Medical Research and Opinion
|
Nov 2004 |
117 |
| 40 |
A model of chronic pain in the rat: functional correlates of alterations in the activity of opioid systems
MJ Millan, Andrzej Członkowski, CW Pilcher et al. · Journal of Neuroscience
Open access |
1987 |
117 |
| 41 |
Enhancement of the Systemic and CNS Specific Delivery of L-Dopa by the Nasal Administration of Its Water Soluble Prodrugs
Huaihung Danny Kao, Ashraf Traboulsi, Soichi Itoh et al. · Pharmaceutical Research
|
Aug 2000 |
117 |
| 42 |
Pharmacokinetics and Tolerability of Lidocaine Patch 5% with Extended Dosing
Arnold R. Gammaitoni, Matthew W. Davis · Annals of Pharmacotherapy
|
Feb 2002 |
111 |
| 43 |
Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations
Jennifer S. Gewandter et al. · Pain
Open access |
24 May 2014 |
111 |
| 44 |
Prostate Cancer Early Detection, Version 1.2014
Peter R. Carroll et al. · Journal of the National Comprehensive Cancer Network
Open access |
Sep 2014 |
107 |
| 45 |
Central Nervous System Cancers, Version 2.2014
Burt Nabors et al. · Journal of the National Comprehensive Cancer Network
Open access |
31 Oct 2014 |
105 |
| 46 |
MorphiDex® (morphine sulfate/dextromethorphan hydrobromide combination) in the treatment of chronic pain: Three multicenter, randomized, double-blind, controlled clinical trials fail to demonstrate enhanced opioid analgesia or reduction in tolerance
Bradley S. Galer, David J. Lee, Tina Ma et al. · Pain
|
21 Apr 2005 |
103 |
| 47 |
Assessment of pain quality in chronic neuropathic and nociceptive pain clinical trials with the Neuropathic Pain Scale
Mark P. Jensen, Robert H. Dworkin, Arnold R. Gammaitoni et al. · Journal of Pain
Open access |
Feb 2005 |
101 |
| 48 |
Ventricular Irritability Associated with the Use of Naloxone Hydrochloride: Two Case Reports and Laboratory Assessment of the Effect of the Drug on Cardiac Excitability
Lawrence L. Michaelis, Paul R. Hickey, Thomas Arkle Clark et al. · The Annals of Thoracic Surgery
|
Dec 1974 |
100 |
| 49 |
Pharmacokinetics and safety of continuously applied lidocaine patches 5%
Arnold R. Gammaitoni, Nancy A. Álvarez, Bradley S. Galer · American Journal of Health-System Pharmacy
|
15 Nov 2002 |
99 |
| 50 |
Lidocaine Patch 5% Reduces Pain Intensity and Interference with Quality of Life in Patients With Postherpetic Neuralgia: An Effectiveness Trial
Nathaniel P. Katz, Arnold R. Gammaitoni, Matthew W. Davis et al. · Pain Medicine
|
Dec 2002 |
98 |